Publications 2012-2003

  1. Schmitt, M. J., Philippidou, D., Reinsbach, S. E., Margue, C., Wienecke-Baldacchino, A., Nashan, D., Behrmann, I., and Kreis S. (2012) Interferon-γ-induced activation of signal transducer and activator of transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells. Cell Commun Signal 10: 41.
  2. Reinsbach, S., Nazarov, P. V., Philippidou, D., Schmitt, M., Wienecke-Baldacchino, A., Muller, A., Vallar, L, Behrmann, I., and Kreis, S. (2012) Dynamic regulation of microRNA expression following Interferon-g-induced gene transcription. RNA Biology 97: 1-12.
  3. Haan, C., Ungureanu, D., Pekkala, T., Silvennoinen, O., and Haan, S. (2012) Regulation of JAKs: Insights gleaned from the functional protein domains. In: “Jak-STAT Signaling: From basics to disease” (T. Decker and M. Müller (eds)); Springer Verlag Wien AU p. 5-26.
  4. Haan, C., Rolvering, C., Raulf, F., Kapp, M., Drückes, P., Thoma, G., Behrmann, I., and Zerwes, H. G. (2011) Jak1 has a dominant role over Jak3 in signal transduction through gc-containing cytokine receptors. Chem Biol 18: 314-323.
  5. Vollmer, S., Haan, C., and Behrmann, I. (2010) Oncostatin M upregulates the ER chaperone grp78/BiP in liver cells. Biochem Pharmacol 80: 2066-2073.
  6. Philippidou, D., Schmitt, M., Moser, D., Margue, C., Nazarov, P. V., Muller, A., Vallar, L., Nashan, D., Behrmann, I., and Kreis, S. (2010) Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res 70: 4163-4173.
  7. Radtke, S., Wüller S., Yang, X.-P., Lippok, B. E., Mütze, B., Mais, C., Schmitz-Van de Leur, H., Bode, J. G., Gaestel, M., Heinrich, P. C., Behrmann, I., Schaper, F., and Hermanns, H. M. (2010) Cross-regulation of cytokine signalling: pro-inflammatory cytokines restrict IL-6 signalling through receptor internalization and degradation. J Cell Sci 125: 947-959.
  8. Margue, C., and Kreis, S. (2010) IL-24: Physiological and supraphysiological effects on normal and malignant cells. Curr Med Chem 17: 3318-3326.
  9. Entschladen, F., Altschmied, J., Baumgrass, R., Behrmann, I., Giehl, K., Hermanns, H., Huber, O., Kieser, A., Klotz, L. O., Kubatzky, K. F., Hass, R., Janssen, O., Friedrich, K. (2010) Signal transduction, receptors, mediators and genes: younger than ever – the 13th meeting of the Signal Transduction Society focused on aging and immunology. Cell Commun Signal 8: 2.
  10. Haan, S., Behrmann, I., and Haan, C. (2010) Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. Review. J Cell Mol Med 14: 504-527.
  11. Wiesinger, M. Y., Haan, S., Wüller, S., Kaufmann, M.E., Recker, T., Küster, A., Heinrich, P. C. and Müller-Newen, G. (2009) Development of an IL-6 inhibitor based on the functional analysis of murine IL-6Ra. Chem Biol 16: 783-794.
  12. Haan, S., Wüller, S., Kaczor, J., Rolvering, C., Nöcker, T., Behrmann, I., and Haan, C. (2009) SOCS-mediated down-regulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling. Oncogene 28: 3069-3080.
  13. Bender, H., Wiesinger, M. Y., Nordhoff, C., Schoenherr, C., Haan, C., Ludwig, S., Weiskirchen, R., Kato, N., Heinrich, P. C., and Haan, S. (2009) Interleukin-27 displays interferon-like functions in human hepatoma cells and hepatocytes. Hepatology 50: 585-591.
  14. Vollmer, S., Kappler, V., Kaczor, J., Flügel, D., Rolvering, C., Kato, N., Kietzmann, T., Behrmann, I., and Haan, C. (2009) Hypoxia-inducible factor is upregulated by Oncostatin M and participates in Oncostatin M signaling. Hepatology 50: 253-260.
  15. Haan, C., Kroy, D., Nöcker, T., Wüller, S., Sommer, U., Behrmann, I., Heinrich, P. C., and Haan, S. (2009) An unusual insertion in Janus kinase 2 is crucial for kinase activity and differentially affects cytokine responses. J Immunol 182: 2969-2977.
  16. Friedrich, K., and Behrmann, I. (2009) Zelluläre Signalprozesse. In: Biochemie und Molekularbiologie des Menschen, Elsevier, Hrsg.: M. Schartl, M. Gessler, A. von Eckardstein pp. 631-669.
  17. Hintzen, C., Haan, C., Tuckermann, J. P., Heinrich, P. C., and Hermanns, H. M. (2008) Oncostatin M-induced and constitutive activation of the Jak2/STAT5/CIS pathway suppresses CCL1, but not CCL7 and CCL8, chemokine expression. J Immunol 181: 7341-7349.
  18. Haan, S., Margue, C., Engrand, A., Rolvering, C., Schmitz-Van de Leur, H., Heinrich, P. C., Behrmann, I., and Haan, C. (2008) Dual role of the Jak1 FERM- and kinase-domains in cytokine receptor binding and in stimulation-dependent Jak activation. J Immunol 180: 998-1007.
  19. Kreis, S., Philippidou, D., Margue, C., and Behrmann, I. (2008) IL-24: a classic cytokine and/or a potential cure for cancer? Review. J Cell Mol Med 12: 2505-2510.
  20. Kreis, S., Philippidou, D., Margue, C., Rolvering, C., Haan, C., Dumontier, L., Renauld, J.-C., and Behrmann, I. (2007) Recombinant IL-24 lacks apoptosis-inducing properties in melanoma cells. PLoS ONE, e1300.
  21. Kreis, S., Munz, G. A., Haan, S., Heinrich, P. C., and Behrmann, I. (2007) Cell-density dependent increase of constitutive STAT3 activity in melanoma cells is mediated by Janus kinases. Mol Cancer Res 5: 1331-1341.
  22. Soond, S. M., Carroll, C., Townsend, P. A., Sayan, E., Melino, G., Behrmann, I., Knight, R. A., Latchman, D. S., Stephanou, A. (2007) STAT1 regulates p73-mediated Bax gene expression. FEBS Lett. 581: 1217-1226.
  23. Komyod, W., Böhm, M., Metze, D., Heinrich, P. C., and Behrmann, I. (2007) Constitutive SOCS3 expression confers a growth advantage to a human melanoma cell line. Mol Cancer Res 5: 271-281.
  24. Haan, C., and Behrmann, I. (2007) A cost-effective non-commercial ECL solution for Western Blot detections yielding strong signals and low background. J Immunol Meth 318: 11-19.
  25. Van Roeyen, C. R. C., Ostendorf, T., Denecke, B., Bokemeyer, D., Behrmann, I., Strutz, F., Lichenstein, H.S., LaRochelle, W. J., Pena, C., Chaudhun, A., and Floege, J. (2006) Biological responses to PDGF-BB versus PDGF-DD in human mesangial cells. Kidney Intern 69: 1393-1402.
  26. Radtke, S., Jörissen, A., Schmitz-Van de Leur, H., Heinrich, P. C., and Behrmann, I. (2006) Three dileucine-like motifs within the interbox1/2 region of the human oncostatin M receptor prevent efficient surface expression in absence of an associated Janus kinase. J Biol Chem 281: 4024-4034.
  27. Hellerbrand, C., Mühlbauer, M., Wallner, S., Schuierer, M., Behrmann, I., Bataille, F., Schölmerich, J., and Bosserhoff, A. K. (2006) Promotor-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma. Carcinogenesis 27: 64-72.
  28. Haan, C., Kreis, S., Margue, C., and Behrmann, I. (2006) Jaks and cytokine receptors – an intimate relationship. Review. Biochem Pharmacol 72: 1538-1546.
  29. Komyod, W., Bauer, U.-M., Heinrich, P. C., Haan, S., and Behrmann, I. (2005) Are STATs arginine-methylated? J Biol Chem 280: 21700-21705.
  30. Radtke*, S., Haan, S.*, Jörissen A. *, Hermanns, H. M., Diefenbach, S., Smyczek, T., Schmitz-Van de Leur, H., Heinrich, P. C., Behrmann I.*, and Haan, C.* (* contributed equally) (2005) The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signalling but plays a structural role for receptor interaction and upregulation of receptor surface expression. J Biol Chem 280: 25760-25765.
  31. Haan, S., Keller, J. F., Behrmann, I., Heinrich, P. C., and Haan, C. (2005) Multiple reasons for an inefficient STAT1 response upon IL-6-type cytokine stimulation. Cell Signal 17: 1542-1550.
  32. Wellbrock, C., Weisser, C., Morcinek, J. C., Becker, J., Vetter, C. S., Behrmann, I., Kortylewski, M., Heinrich, P. C., Fischer, P., and Schartl, M. (2005) STAT5 activation by interferon-alpha counteracts STAT1 induced signalling and contributes to interferon resistance of melanoma cells. Curr Biol 15: 1629-1639.
  33. Kortylewski, M., Komyod, W., Kauffmann, M.-E., Bosserhoff, A., Heinrich, P. C., and Behrmann, I. (2004) IFN- g mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals. J Inv Derm 122: 414-422.
  34. Fischer, P., Lehmann, U., Sobota, R. M., Schmitz, J., Niemand, C., Linnemann S., Haan, S., Behrmann, I., Yoshimura A., Johnston, J. A., Müller-Newen, G., Heinrich, P. C., and Schaper, F. (2004) The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signalling. Biochem J 378: 449-460.
  35. Behrmann, I., Smyczek, T., Heinrich, P. C., Schmitz-Van De Leur, H., Komyod, W., Giese, B., Müller-Newen, G., Haan, S. and Haan, C. 2004. Jak subcellular localisation revisited:The exclusive membrane-localisation of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak/receptor complex to be equivalent to a receptor tyrosine kinase. J Biol Chem 279: 35486-35498.
  36. Lehmann, U., Schmitz, J., Weissenbach, M., Hörtner, M., Friederichs, K., Behrmann, I., Tsiaris, W., Sasaki, A., Schneider-Mergener, J., Yoshimura, A., Neel, B. G., Heinrich, P. C. and Schaper, F. 2003. SHP-2 and SOCS3 contribute to Y759-dependent attenuation of IL-6 signaling through gp130. J Biol Chem 278: 661-671.
  37. Kortylewski, M., Feld, F., Krüger, K. D., Bahrenberg, G., Roth, R. A., Heinrich, P. C., Joost, H. G., Behrmann, I., and Barthel, A. (2003) Akt modulates STAT3-mediated gene expression through a FKHR (FOXO1a)-dependent mechanism. J Biol Chem 278: 5242-5249.
  38. Behrmann, I., Wallner, S., Komyod, W., Heinrich, P. C., Buettner, R., and Bosserhoff, A. K. (2003) Characterization of methylthioadenosine phosphorylase (MTAP) expression in malignant melanoma. Am J Path 163: 683-690.
  39. Giese, B., Au-Yeung, C. K., Herrmann, A., Haan, C., Diefenbach, S., Küster, A., Wortmann, S., Roderburg, C., Heinrich, P. C., Behrmann, I. and Müller-Newen, G. (2003) Long term association of the cytokine receptor gp130 and the Janus kinase Jak1 revealed by FRAP analysis. J Biol Chem 278: 39205-39213.
  40. Heinrich, P. C., Behrmann, I., Haan, S., Hermanns, H. M., Müller-Newen, G., and Schaper, F. (2003). Principles of IL-6-type cytokine signaling and its regulation. Review. Biochem J 374: 1-20.